StockNews.com Initiates Coverage on Regulus Therapeutics (NASDAQ:RGLS)

StockNews.com started coverage on shares of Regulus Therapeutics (NASDAQ:RGLS) in a research report report published on Tuesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also weighed in on the stock. Wells Fargo & Company lifted their price objective on shares of Regulus Therapeutics from $2.00 to $3.00 and gave the company an equal weight rating in a research report on Wednesday, March 13th. HC Wainwright reissued a buy rating and issued a $9.00 target price on shares of Regulus Therapeutics in a report on Monday, March 25th. SVB Leerink began coverage on Regulus Therapeutics in a report on Monday, March 18th. They issued an outperform rating and a $6.00 target price for the company. Leerink Partnrs reissued an outperform rating on shares of Regulus Therapeutics in a report on Monday, March 18th. Finally, Canaccord Genuity Group reduced their target price on Regulus Therapeutics from $12.00 to $11.00 and set a buy rating for the company in a report on Tuesday, March 19th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average price target of $7.25.

Regulus Therapeutics Trading Down 5.1 %

Shares of RGLS opened at $2.22 on Tuesday. The firm has a market cap of $145.33 million, a PE ratio of -1.40 and a beta of 1.57. The company’s 50 day simple moving average is $2.12 and its 200-day simple moving average is $1.59. Regulus Therapeutics has a 12-month low of $1.08 and a 12-month high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.40). As a group, equities research analysts forecast that Regulus Therapeutics will post -0.52 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in RGLS. Vanguard Group Inc. raised its stake in shares of Regulus Therapeutics by 21.4% during the 1st quarter. Vanguard Group Inc. now owns 3,678,334 shares of the biopharmaceutical company’s stock worth $1,096,000 after buying an additional 648,121 shares during the last quarter. Federated Hermes Inc. purchased a new stake in Regulus Therapeutics during the 1st quarter worth about $8,656,000. Northern Trust Corp increased its position in Regulus Therapeutics by 42.9% during the 1st quarter. Northern Trust Corp now owns 168,172 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 50,518 shares in the last quarter. Renaissance Technologies LLC increased its position in Regulus Therapeutics by 498.2% during the 1st quarter. Renaissance Technologies LLC now owns 133,400 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 111,100 shares in the last quarter. Finally, Dimensional Fund Advisors LP purchased a new stake in Regulus Therapeutics during the 3rd quarter worth about $54,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.